对于选择性向KRAS突变癌细胞的斯坦丁染料结合物
bioRxiv : the preprint server for biology
|June 12, 2025
概括
类他类药物通过增强巨型皮诺细胞形成来选择性地向KRAS突变的胰腺癌细胞. 斯坦丁染料合物在KRAS突变癌症治疗中表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物运输 药物运输 药物运输
背景情况:
- 超过90%的胰腺管腺癌 (PDAC) 患者携带KRAS突变 (KRASMUT),治疗选择有限.
- 类药物对KRAS转化细胞表现出选择性毒性,这表明有针对性治疗的潜力.
研究的目的:
- 为了研究KRASMUT细胞对他类药物的选择性摄取.
- 评估他类染料结合物作为KRASMUT胰腺癌细胞 (PCC) 的向输送载体.
主要方法:
- 合成的simvastatin-和pravastatin-dye (Cy5.5) 结合物. 这种结合物可以在药物中使用.
- 在KRASMUT和KRAS野生型 (KRASWT) 细胞和PDAC共同培养模型中评估结合体吸收.
- 在PCC和癌症相关纤维细胞 (CAF) 中评估结合体诱导的细胞死亡.
主要成果:
- 通过增加的宏皮诺细胞化,斯坦丁染料合物在KRASMUT细胞中显著增强了摄取,与KRASWT细胞相比.
- 在PTEN缺乏的MCF10A细胞中也观察到增强的吸收,这种细胞因巨细胞细胞增高而闻名.
- 普拉瓦斯塔丁-Cy5.5在共同培养模型中选择性地杀死KRASMUTPCC,而不会影响KRASWTCAFs.
结论:
- 斯坦丁染料结合物通过增强的宏皮诺细胞分裂被KRASMUT癌细胞选择性地吸收.
- 这些合物显示出KRASMUT癌症治疗的向传递系统的潜力.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


